{"case_name": "Sight Sciences, Inc. v. Ivantis, Inc.", "case_number": "21-1317", "judge": "Magistrate Judge Sherry R. Fallon", "date": "03-23-2023", "ocr_text": "IN THE UNITED STATES DISTRICT COURT \nFOR THE DISTRICT OF DELA WARE \nSIGHT SCIENCES, INC., ) \n) \nPlaintiff, ) \n) \n\ufffd ) \n) \nIV ANTIS, INC., ALCON RESEARCH ) \nLLC, ALCON VISION, LLC, & ALCON ) \nINC., ) \n) \nDefendants. ) Civil Action No. 21-1317-GBW-SRF \nREPORT AND RECOMMENDATION \nPending before the court are the parties' claim construction disputes. Plaintiff Sight \nSciences, Inc. (\"Plaintiff' ) asserts five patents against defendants Ivantis, Inc., Alcon Research \nLLC, Alcon Vision, LLC, and Alcon Inc. ( collectively, \"Defendants\" ): United States Patent Nos. \n8,287,482 (\"the '482 patent\"), 9,370,443 (\"the '443 patent\"), 9,486,361 (\"the '361 patent\"), \n10,314,742 (\"the '742 patent\"), and 11,389,328 (\"the '328 patent;\" collectively, the \"Asserted \nPatents\"). (D.I. 59 at 1124-29) All of the asserted patents share substantially identical \nspecifications and generally relate to devices, methods, and kits for reducing intraocular pressure \nin the treatment of glaucoma. (D.I. 119, Exs. 1-5) This decision sets forth the court's \nrecommendations of constructions following a review of the parties' joint claim construction \nbrief and consideration of the arguments presented at the Markman hearing held on February 9, \n2023. (D.I. 118) \nThe parties present argument on ten disputed claim terms. For the reasons set forth \nbelow, I recommend that the court adopt the following constructions for the disputed terms: "}